• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hologic braces against a potential takeover

Hologic braces against a potential takeover

November 21, 2013 By Arezu Sarvestani

Hologic takes the defense against a possible takeover

Massachusetts-based Hologic (NSDQ:HOLX) announced today that it adopted a stockholder rights plan, just as activist investor Carl Icahn nabbed up more than 12.6% of the company.

Icahn acquired about $285.4 million in HOLX shares, SEC documents show, and he’s already got some ideas for change at the women’s health devices maker. Hologic was quick to adopt a 1-year rights plan to defend the company against a hostile takeover.

HOLX shares jumped 2.3% today, trading at $22.80 as of about 12:15 p.m.

Icahn, who has a reputation for making waves at companies he takes big stakes in, said in a regulatory filing that he took an interest in Hologic because he felt its shares were undervalued, and he may seek a seat on Hologic’s board.

The medical device maker took little time in announcing its rights plan, which grants stockholders 1 right for each common stock share they own and gives investors the ability to buy into a new series of preferred stock should anyone try to nab a 10% or larger stake in the company, according to a press release.

The defensive tactics got a harsh reaction from International Strategy & Investment Group analyst Vijay Kumar, who told Bloomberg that Hologic’s board had "lost its street credibility" and that it would likely be booted in March.

The shakeup comes amid a tough year for Hologic, with sales expected to take a hit as the device maker faces reimbursement woes and pricing pressures.

The company earlier this month released a quarterly and full-year earnings report that beat analysts’ expectations, but a hefty $1.1 billion impairment charge devastated the device maker’s bottom line. The impairment charge was a result of recalculated goodwill for Hologic’s diagnostics business, the company said.

For the full year, Hologic posted losses of $1.17 billion, or $4.36 per share, on sales of $2.51 billion. That compared with losses of $73.6 million, or 28¢ per share, on sales of $2.01 billion in 2012. Adjusted for 1-time costs, Hologic reported earnings of $1.50, again beating Wall Street by 2¢.

Filed Under: News Well, Wall Street Beat Tagged With: Hologic

More recent news

  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt
  • Penumbra completes enrollment in pulmonary embolism trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy